<DOC>
	<DOCNO>NCT01914562</DOCNO>
	<brief_summary>This open label , randomize , balance , single center , single dose , trial ass pharmacokinetic ( PK ) profile OCA , glyco-OCA tauro-OCA empty stomach ( fasted condition ) follow high fat , high calorie meal ( fed condition ) 2-period , 2-sequence , crossover manner .</brief_summary>
	<brief_title>Effect Food Pharmacokinetics Obeticholic Acid ( OCA )</brief_title>
	<detailed_description />
	<mesh_term>Chenodeoxycholic Acid</mesh_term>
	<criteria>Subjects require meet follow criterion order include trial . 1 . Male female subject 18 55 year 2 . Contraception : Female subject must postmenopausal , surgically sterile , premenopausal , prepare use 1 effective ( â‰¤ 1 % failure rate ) method contraception trial least 30 day last dose OCA . Effective method contraception consider : 1 . Double barrier method , ie , ( ) condom ( male female ) spermicide ( b ) diaphragm spermicide 2 . Intrauterine device ( IUD ) 3 . Vasectomy 3 . Good general health determine medical history , result physical examination , vital sign , electrocardiogram ( ECG ) , clinical laboratory test obtain within 14 day prior Day 0 4 . Body mass index ( BMI ) 18 28 ; BMI determine follow equation : BMI = weight/height2 ( kg/m2 ) . 5 . Willing abstain alcohol , caffeine , xanthinecontaining food beverage 72 hour prior period check participation inpatient period trial 6 . Willing able give write informed consent Subjects meet follow criterion exclude trial . 1 . Prior participation clinical trial OCA ( INT747 ; 6ECDCA ) 2 . History presence disease condition know interfere absorption , distribution , metabolism , excretion drug include bile salt metabolism large intestine , eg , inflammatory bowel disease 3 . History gastrointestinal surgery gall bladder removal ( cholecystectomy ) 4 . History presence clinically significant cardiovascular , hepatic , diabetic , gastrointestinal , metabolic , neurologic , pulmonary , endocrine , psychiatric , neoplastic disorder ( ) 5 . History know suspect clinically significant hypersensitivity drug , aside penicillin 6 . Ingestion prescription medication within 14 day prior Day 0 ingestion counter medication within 7 day prior Day 0 7 . Participation radiologic examination involve parenteral administration iodinate contrast material within 2 week prior screen , subsequently , end trial participation 8 . History presence alcohol abuse ( define consumption 210 mL alcohol per week ; equivalent fourteen 4 ounce ( oz ) glass wine , fourteen 12 oz cans/bottles beer wine cooler per week ) 9 . History presence substance abuse within past 2 year positive drug screen test 10 . Smoker user tobacco nicotine product 11 . Any screening laboratory test result within normal reference range consider clinically significant 12 . Participation another investigational drug trial within 30 day prior Day 0 13 . History noncompliance medical regimen , subject consider potentially unreliable 14 . Blood plasma donation within 30 day prior Day 0 15 . Mental instability incompetence 16 . Presence human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>